11990712

Source:http://linkedlifedata.com/resource/pubmed/id/11990712

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0008059, umls-concept:C0008838, umls-concept:C0034897, umls-concept:C0146224, umls-concept:C0280100, umls-concept:C0920321, umls-concept:C1516476, umls-concept:C2603343
pubmed:issue	2
pubmed:dateCreated	2002-5-6
pubmed:abstractText	To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of cisplatin after a 72-hour continuous infusion of topotecan.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/CA 02649, http://linkedlifedata.com/resource/pubmed/grant/CA 02971, http://linkedlifedata.com/resource/pubmed/grant/CA 03750, http://linkedlifedata.com/resource/pubmed/grant/CA 03888, http://linkedlifedata.com/resource/pubmed/grant/CA 05436, http://linkedlifedata.com/resource/pubmed/grant/CA 07306, http://linkedlifedata.com/resource/pubmed/grant/CA 10382, http://linkedlifedata.com/resource/pubmed/grant/CA 13539, http://linkedlifedata.com/resource/pubmed/grant/CA 14560, http://linkedlifedata.com/resource/pubmed/grant/CA 17829, http://linkedlifedata.com/resource/pubmed/grant/CA 26126, http://linkedlifedata.com/resource/pubmed/grant/CA 28882, http://linkedlifedata.com/resource/pubmed/grant/CA 36015, http://linkedlifedata.com/resource/pubmed/grant/CA 42764
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9505928
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin, http://linkedlifedata.com/resource/pubmed/chemical/Granulocyte Colony-Stimulating..., http://linkedlifedata.com/resource/pubmed/chemical/Topotecan
pubmed:status	MEDLINE
pubmed:month	Feb
pubmed:issn	1077-4114
pubmed:author	pubmed-author:AmesMatthew MMM, pubmed-author:KrailoMark DMD, pubmed-author:MaresWen LieuWL, pubmed-author:MosherRevondaR, pubmed-author:ReamanGregory HGH, pubmed-author:ReidJoel MJM, pubmed-author:SeibelNita LNL, pubmed-author:WellsRobert JRJ, pubmed-author:WiersmaSusan RSR
pubmed:issnType	Print
pubmed:volume	24
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	89-93
pubmed:dateRevised	2011-10-6
pubmed:meshHeading	pubmed-meshheading:11990712-Adolescent, pubmed-meshheading:11990712-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:11990712-Bone Marrow, pubmed-meshheading:11990712-Child, pubmed-meshheading:11990712-Child, Preschool, pubmed-meshheading:11990712-Cisplatin, pubmed-meshheading:11990712-Female, pubmed-meshheading:11990712-Granulocyte Colony-Stimulating Factor, pubmed-meshheading:11990712-Humans, pubmed-meshheading:11990712-Infusions, Intravenous, pubmed-meshheading:11990712-Male, pubmed-meshheading:11990712-Maximum Tolerated Dose, pubmed-meshheading:11990712-Neoplasm Recurrence, Local, pubmed-meshheading:11990712-Neoplasms, pubmed-meshheading:11990712-Neutropenia, pubmed-meshheading:11990712-Rhabdomyosarcoma, pubmed-meshheading:11990712-Salvage Therapy, pubmed-meshheading:11990712-Topotecan, pubmed-meshheading:11990712-Treatment Outcome
pubmed:year	2002
pubmed:articleTitle	Phase I trial of cisplatin and topotecan in children with recurrent solid tumors: Children's Cancer Group Study 0942.
pubmed:affiliation	Children's Hospital Research Foundation, Cincinnati, Ohio, USA. robert.wells@chmcc.org
pubmed:publicationType	Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase I